Supplemental Table 3. Neuromuscular blocker dose, reversal dose, pre reversal assessment and post reversal assessment specific only to the manually collected anesthesia records dataset (n=2807). Only data collected for the implementation ramp up period is shown.

|  |  |
| --- | --- |
|  | Implementation ramp up 10/01/2018 - 1/31/2020 |
| Number patient surgeries | 997 |
| Weight kg, mean ±SD | 83 ±24 |
| Neuromuscular blocker dose, mg mean ±SD |
|  Cisatracurium | 29 ±40 |
|  Rocuronium | 72 ±49 |
| Pre-reversal TOF count, median [25th, 75th percentile] |
|  Overall | 4 [2,4], N=814 |
|  Neostigmine | 4 [4,4], N=370 |
|  Sugammadex | 2 [1,4], N=444 |
| Pre-reversal TOF count, number (%) |
|  TOF count = 4 | 428/997 (43%)  |
|  TOF count < 4 | 386/997 (39%) |
|  TOF count missing | 183/997 (18%) |
| Reversal dose, mg, mean ±SD |
|  Neostigmine | 4 ±1 |
|  Sugammadex | 222 ±106 |
| OR Assessment overall, number (%) |
|  Not recorded | 67/997 (7%) |
|  Qualitative | 471/997 (47%) |
|  TOF ratio ≥ 0.9 | 449/997 (45%) |
|  TOF ratio < 0.9 | 10/997 (1%) |
| TOF ratio for TOF ratio ≥ 0.9 cases, mean ±SD |
|  Neostigmine | 1.0 ±0.1, N=134 |
|  Sugammadex | 1.1 ±0.1, N=286 |
|  No reversal | 1.1 ±0.2, N=39 |